ClinicalTrials.gg
Not yet recruitingNCT07256509Updated Dec 5, 2025

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

A Phase 2 interventional study of SYS6010 and Osimertinib in Non-Small Cell Lung Cancer, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited — 11 open to participants now, 12 under way, 7 of them phase 3. Carcinoma, Non-Small-Cell Lung · CSPC Pharmaceutical Group Limited.

Planned enrollment
14th of 16
120 · median 365
Started
2025
with 2 others
Phase 2
4 of 17
2 open now
Primary completion
2026-11
later than 4 of 11 live
Registered
13th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.

Read the detailed description

This study includes three stages: a neoadjuvant therapy stage, a surgery stage, and an adjuvant follow-up stage. In the neoadjuvant therapy stage, eligible participants will be stratified by stage (Stage II and Stage III) and mutation type (19Del and L858R) and randomized in a 1:1 ratio to the SYS6010 combined with osimertinib treatment group and the osimertinib monotherapy group. Neoadjuvant therapy will be administered for 3 cycles.

In the surgery stage, the feasibility of surgery will be assessed by a thoracic surgery investigator. Surgery should be performed between Week 10 and Week 12 (i.e., D64-D84 after the first dose of neoadjuvant therapy). Tumor samples collected during surgery will be sent to a central pathology laboratory to assess pathological response.

In the adjuvant therapy stage, all participants who undergo surgery will subsequently enter the adjuvant therapy stage. Participants who do not undergo surgery for reasons other than disease progression will also enter the adjuvant therapy stage.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and voluntarily sign the written form (ICF);
  2. Age 18-75 years, regardless of sex;
  3. or cytologically confirmed non-squamous non-small cell lung cancer, staged as resectable or potentially resectable Stage II-IIIB disease according to the International Association for the Study of Lung Cancer (IASLC) 8th Edition TNM staging criteria;
  4. Must be eligible for complete surgical resection of the primary tumor;
  5. Nodal status must be evaluated by whole-body FDG-PET and contrast-enhanced CT;
  6. Confirmed presence of an EGFR-sensitizing mutation (exon 19 deletion or exon 21 L858R mutation, co-mutation with other EGFR sites is allowed), as tested by a central laboratory or local testing facility;
  7. No prior systemic anti-tumor therapy (including chemotherapy, biotherapy, targeted therapy, immunotherapy);
  8. At least one at baseline as defined by (RECIST) v1.1;
  9. (ECOG) performance status (PS) score of 0 or 1;
  10. ≥6 months;
  11. Adequate major organ and bone marrow function;
  12. Women or men of must use highly effective .

1. Able to understand and voluntarily sign the written informed consent form (ICF); 2. Age 18-75 years, regardless of sex; 3. Histologically or cytologically confirmed non-squamous non-small cell lung cancer, staged as resectable or potentially resectable Stage II-IIIB disease according to the International Association for the Study of Lung Cancer (IASLC) 8th Edition TNM staging criteria; 4. Must be eligible for complete surgical resection of the primary tumor; 5. Nodal status must be evaluated by whole-body FDG-PET and contrast-enhanced CT; 6. Confirmed presence of an EGFR-sensitizing mutation (exon 19 deletion or exon 21 L858R mutation, co-mutation with other EGFR sites is allowed), as tested by a central laboratory or local testing facility; 7. No prior systemic anti-tumor therapy (including chemotherapy, biotherapy, targeted therapy, immunotherapy); 8. At least one measurable lesion at baseline as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; 9. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 10. Life expectancy ≥6 months; 11. Adequate major organ and bone marrow function; 12. Women or men of childbearing potential must use highly effective contraception.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of Stage I, Stage IIIB with N3, and Stage IIIC, IVA, and IVB non-small cell lung cancer;
  2. Multiple primary (refer to exclusion criterion #8 for synchronous primary lung cancer) OR a mixed histology of SCLC and NSCLC;
  3. T4 stage lung cancer due to invasion of the great vessels, carina, trachea, esophagus, heart, or vertebral body; and/or bulky N2 disease;
  4. Eligible only for segmentectomy or wedge resection;
  5. Receipt of Chinese patent medicine preparations indicated for the treatment of lung cancer within 1 week before randomization;
  6. Major surgery or severe traumatic injury within 4 weeks before the first study treatment, or expected to undergo major surgery during the study period;
  7. History of other primary malignant tumor (including any known or suspected concurrent primary lung cancer);
  8. History of disease, immunodeficiency, or organ transplant (except for corneal transplant);
  9. nausea, vomiting, chronic gastrointestinal disease, inability to swallow drugs orally;
  10. Evidence of severe or uncontrolled medical conditions (including uncontrolled hypertension, diabetes mellitus, etc,);
  11. Active or prior history of interstitial lung disease (ILD)/pneumonitis;
  12. Expected to receive therapy within 30 days after randomization;
  13. History of a definite neurological or mental disorder; known allergy, , or intolerance to the study drugs or any of their ;
  14. Pregnant or lactating women;
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    SYS6010 + Osimertinib

    Neoadjuvant Therapy: SYS6010 + Osimertinib Adjuvant Therapy: Osimertinib + Pemetrexed + Cisplatin or Carboplatin

    Drug: SYS6010 · Drug: Osimertinib

  • Active comparator
    Osimertinib

    Neoadjuvant Therapy: Osimertinib Adjuvant Therapy: Osimertinib + Pemetrexed + Cisplatin or Carboplatin

    Drug: Osimertinib · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin

Interventions

  • SYS6010 by intravenous (IV) infusion

  • Osimertinib, oral

    Also known as: Osimertinib Mesylate Tablets

  • 500 mg/m\^2 by IV infusion, Q3W

  • 75 mg/m\^2 by IV infusion, Q3W

  • AUC 5 mg/mL•min by IV infusion, Q3W

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR) Rate

    Defined as the proportion of participants with ≤10% residual viable tumor cells in the resected primary tumor bed, as assessed by blinded independent pathological review (BIPR).

    Time frame: Within 8 weeks post-surgery

  2. Pathological Complete Response (pCR) Rate

    The proportion of participants with no residual viable tumor cells in both the resected primary tumor bed and lymph nodes, as assessed by BIPR.

    Time frame: Within 8 weeks post-surgery

  3. Downstaging from N2 to N0/N1 or N1 to N0 at the time of surgery

    Time frame: Within 8 weeks post-surgery

  4. Disease-Free Survival (DFS)

    Investigator-assessed DFS per RECIST v1.1

    Time frame: Up to approximately 5.5 years after the last participant enrolled

  5. Event-Free Survival (EFS)

    Investigator-assessed DFS per RECIST v1.1

    Time frame: Up to approximately 5.5 years after the last participant enrolled

  6. Objective Response Rate (ORR)

    Investigator-assessed ORR per RECIST v1.1

    Time frame: Up to approximately 5.5 years after the last participant enrolled

  7. Overall Survival (OS)

    Time frame: Up to approximately 5.5 years after the last participant enrolled

  8. Incidence of Adverse Events (AEs)

    Time frame: Up to approximately 5.5 years after the last participant enrolled

  9. Anti-drug Antibodies (ADAs) to SYS6010

    Time frame: Up to approximately 5.5 years after the last participant enrolled

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Nov 2026, 12 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 12 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 1, 2025
StartEst.
Nov 30, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Jun 30, 2032
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07256509
Responsible party
Sponsor
First posted
Dec 1, 2025
Start date
Nov 30, 2025 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Jun 30, 2032 (estimated)
Last update
Dec 5, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
+86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-EGFR Antibody-drug Conjugate CPO301

Start the discussion